Evicenter
MarkdownMedical informationP&T meetings
Tinlarebant (LBS-008)

Stargardt disease type 1

Manufacturer
Belite Bio
Last updated
65 sources

Section 6 of 6

References

65 sources

  1. Abu Serhan et al. (2026) (opens in a new tab)
  2. American Academy of Ophthalmology (2022) (opens in a new tab)
  3. ANZCTR ACTRN12624000031561 (opens in a new tab)
  4. ARVO Annual Meeting (2023) (opens in a new tab)
  5. Aziz et al. (2021) (opens in a new tab)
  6. Belite Bio (opens in a new tab)
  7. Belite Bio (2023) (opens in a new tab)
  8. Belite Bio (2024) (opens in a new tab)
  9. Belite Bio ASRS oral presentation announcement (2026) (opens in a new tab)
  10. Belite Bio Commercial Day (2026) (opens in a new tab)
  11. Belite Bio company presentation (2026) (opens in a new tab)
  12. Belite Bio DRAGON topline results announcement (2025) (opens in a new tab)
  13. Belite Bio FDA Breakthrough Therapy designation announcement (2025) (opens in a new tab)
  14. Belite Bio FDA NDA acceptance announcement (2026) (opens in a new tab)
  15. Belite Bio first quarter 2026 results announcement (2026) (opens in a new tab)
  16. Belite Bio Form 20-F (2026) (opens in a new tab)
  17. Belite Bio Japan NDA submission announcement (2026) (opens in a new tab)
  18. Belite Bio NDA rolling submission completion announcement (2026) (opens in a new tab)
  19. Belite Bio second quarter 2026 results announcement (2026) (opens in a new tab)
  20. Bernstein et al. (2026) (opens in a new tab)
  21. Bodenbender et al. (2025) (opens in a new tab)
  22. Britten-Jones et al. (2025) (opens in a new tab)
  23. Cioffi (2025) (opens in a new tab)
  24. ClinicalTrials.gov NCT05244304 (opens in a new tab)
  25. ClinicalTrials.gov NCT05266014 (opens in a new tab)
  26. ClinicalTrials.gov NCT06388083 (opens in a new tab)
  27. Dayma et al. (2025) (opens in a new tab)
  28. Edwards et al. (2026) (opens in a new tab)
  29. FDA Orphan Drug Designations and Approvals (2017) (opens in a new tab)
  30. Federspiel et al. (2018) (opens in a new tab)
  31. Fujinami et al. (2024) (opens in a new tab)
  32. Gomes et al. (2022) (opens in a new tab)
  33. Gong et al. (2021) (opens in a new tab)
  34. Grigg et al. (2022) (opens in a new tab)
  35. Grigg et al. (2023) (opens in a new tab)
  36. Grigg et al. (2024) (opens in a new tab)
  37. Hoang et al. (2026) (opens in a new tab)
  38. Ibukun et al. (2026) (opens in a new tab)
  39. Kay et al. (2026) (opens in a new tab)
  40. Knott et al. (2023) (opens in a new tab)
  41. Kong et al. (2018) (opens in a new tab)
  42. Kootstra et al. (2026) (opens in a new tab)
  43. Mata et al. (2025) (opens in a new tab)
  44. Mayo Clinic (opens in a new tab)
  45. MedlinePlus Genetics (opens in a new tab)
  46. National Eye Institute (2024) (opens in a new tab)
  47. Ng et al. (2024) (opens in a new tab)
  48. Palmgren et al. (2026) (opens in a new tab)
  49. Parameswarappa et al. (2026) (opens in a new tab)
  50. Polasek et al. (2026) (opens in a new tab)
  51. Retina South Africa (2025) (opens in a new tab)
  52. Roborel de Climens et al. (2021) (opens in a new tab)
  53. Runhart et al. (2022) (opens in a new tab)
  54. Selleck Chemicals (opens in a new tab)
  55. Stanford Health Care (opens in a new tab)
  56. Stargardt disease patient-listening-session report (2022) (opens in a new tab)
  57. Strauss et al. (2016) (opens in a new tab)
  58. Strauss et al. (2023) (opens in a new tab)
  59. Sui et al. (2025) (opens in a new tab)
  60. Terheyden et al. (2022) (opens in a new tab)
  61. UCSF Health (opens in a new tab)
  62. UK Health Research Authority (opens in a new tab)
  63. UK Health Research Authority (2021) (opens in a new tab)
  64. Vaccaro et al. (2023) (opens in a new tab)
  65. Waugh et al. (2018) (opens in a new tab)